Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Monday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.00 price target on shares of Aptose Biosciences in a report on Tuesday, December 10th.

Aptose Biosciences Stock Up 0.5 %

NASDAQ APTO opened at $0.25 on Monday. Aptose Biosciences has a 52 week low of $0.13 and a 52 week high of $2.68. The company has a market capitalization of $15.05 million, a P/E ratio of -0.08 and a beta of 1.06. The stock’s 50-day moving average price is $0.29 and its 200-day moving average price is $0.46.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC bought a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences as of its most recent filing with the Securities & Exchange Commission. 26.62% of the stock is owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.